PharmaPoint: Prostate Cancer - Japan Drug Forecast and Market Analysis to 2022


#163764

168pages

GlobalData

$ 4995

In Stock

PharmaPoint: Prostate Cancer - Japan Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Japan Drug Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

In Japan, PSA screening is used much less frequently than in any of the other major markets discussed in this report. In contrast to the US, where the USPSTF has recommended against the use of routine PSA screening, the Japanese government has increased funding for routine PSA screening and physicians are expected to incorporate it into yearly physical exams (Kamidono et al., 2008). 

A suspected diagnosis of prostate cancer based on elevated PSA levels, symptoms, or an irregular DRE is confirmed using TRUS-guided multiple core needle biopsies. Metastases are diagnosed using bone scans, CT scans, or MRI (CRCJUA, 2005).

Scope

  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Prostate cancer market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in Japan
  • Obtain sales forecast from 2012-2022 in Japan
Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14

4 Disease Management 15
4.1 Diagnosis and Referral Overview 15
4.2 Treatment Overview 17
4.2.1 Conservative Management Strategies 21
4.2.2 Localized Treatments 22
4.2.3 Hormone Therapy 23
4.2.4 Drug Therapies 25
4.3 Japan 26
4.3.1 Diagnosis 26
4.3.2 Clinical Practice 26

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
5.3 Product Profiles - Major Brands, Hormone Therapies 32
5.3.1 Zoladex (goserelin acetate) 32
5.3.2 Lupron Depot (leuprolide acetate) 35
5.3.3 Eligard (leuprolide acetate) 39
5.3.4 Trelstar (triptorelin acetate) 43
5.3.5 Firmagon (degarelix) 46
5.3.6 Casodex (bicalutamide) 49
5.4 Product Profiles - Major Brands, Chemotherapies 53
5.4.1 Taxotere (docetaxel) 53
5.4.2 Jevtana (cabazitaxel) 56
5.5 Product Profiles - Major Brands, Therapeutic Vaccines 60
5.5.1 Provenge (sipuleucil-T) 60
5.6 Product Profiles - Major Brands, Targeted Therapies 65
5.6.1 Zytiga (abiraterone acetate) 65
5.6.2 Xtandi (enzalutamide) 69
5.7 Product Profiles - Major Brands, Bone Therapies 74
5.7.1 Xgeva (denosumab) 74
5.7.2 Zometa (zoledronic acid) 77
5.8 Other Marketed Hormone and Drug Therapies 80

6 Opportunity and Unmet Need 81
6.1 Overview 81
6.2 Efficacy at Prolonging Overall Survival 82
6.3 Safety 82
6.4 Mitigation of Symptoms 83
6.5 Cost 83
6.6 Convenient Routes of Administration 83
6.7 Accurate Diagnostic Tests and Surveillance Tools 84
6.8 Unmet Needs Gap Analysis 84
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 86

7 Pipeline Assessment 87
7.1 Overview 87
7.2 Promising Drugs in Clinical Development 88
7.2.1 Cabozantinib 90
7.2.2 Custirsen Sodium 94
7.2.3 Sprycel (dasatinib) 99
7.2.4 Yervoy (ipilimumab) 103
7.2.5 Orteronel 108
7.2.6 Alpharadin (radium-223 chloride) 112
7.2.7 Tasquinimod 117
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 121

8 Market Outlook 127
8.1 Japan 127
8.1.1 Forecast 127
8.1.2 Key Events 130
8.1.3 Drivers and Barriers 130

9 Appendix 133
9.1 Bibliography 133
9.2 Abbreviations 146
9.3 Methodology 148
9.4 Forecasting Methodology 148
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 148
9.4.2 Percent Drug-treated Patients 149
9.4.3 Percent Hormone Therapy-Treated Patients 149
9.4.4 Drugs Included in Each Therapeutic Class 149
9.4.5 Launch, Patent and Market Exclusivity Expiry Dates 150
9.4.6 General Pricing Assumptions 152
9.4.7 Individual Drug Assumptions 154
9.4.8 Generic Erosion 163
9.4.9 Pricing of Pipeline Agents 163
9.5 Physicians and Specialists Included in This Study 164
9.6 Survey of Prescribing Physicians 165
9.7 About the Authors 166
9.7.1 Authors 166
9.7.2 Global Head of Healthcare 167
9.8 About GlobalData 168
9.9 Contact Us 168
9.10 Disclaimer 168

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13
Table 2: Global Variations in Recommendations on Routine PSA Screening 15
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 20
Table 5: Leading Treatments for Prostate Cancer, 2012 31
Table 6: Product Profile - Zoladex 33
Table 7: Zoladex SWOT Analysis, 2012 35
Table 8: Product Profile - Lupron Depot 36
Table 9: Lupron Depot SWOT Analysis, 2012 38
Table 10: Product Profile - Eligard 40
Table 11: Eligard SWOT Analysis, 2012 42
Table 12: Product Profile - Trelstar 44
Table 13: Trelstar SWOT Analysis, 2012 45
Table 14: Product Profile - Firmagon 46
Table 15: Firmagon SWOT Analysis, 2012 48
Table 16: Product Profile - Casodex 50
Table 17: Casodex SWOT Analysis, 2012 52
Table 18: Product Profile - Taxotere 54
Table 19: Taxotere SWOT Analysis, 2012 56
Table 20: Product Profile - Jevtana 57
Table 21: Jevtana SWOT Analysis, 2012 59
Table 22: Product Profile - Provenge 60
Table 23: Provenge SWOT Analysis, 2012 64
Table 24: Product Profile - Zytiga 66
Table 25: Zytiga SWOT Analysis, 2012 68
Table 26: Product Profile - Xtandi 71
Table 27: Xtandi SWOT Analysis, 2012 73
Table 28: Product Profile - Xgeva 75
Table 29: Xgeva SWOT Analysis, 2012 77
Table 30: Product Profile - Zometa 78
Table 31: Zometa SWOT Analysis, 2012 80
Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012 80
Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 81
Table 34: Overall Unmet Needs, CRPC - Current Level of Attainment 82
Table 35: Clinical Unmet Needs - Gap Analysis, 2012 85
Table 36: Prostate Cancer - Phase III Pipeline, 2012 88
Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 88
Table 38: Product Profile - Cabozantinib 90
Table 39: Cabozantinib SWOT Analysis, 2012 94
Table 40: Product Profile - Custirsen Sodium 95
Table 41: Custirsen Sodium SWOT Analysis, 2012 98
Table 42: Product Profile - Sprycel 99
Table 43: Sprycel SWOT Analysis, 2012 102
Table 44: Product Profile - Yervoy 103
Table 45: Yervoy SWOT Analysis, 2012 107
Table 46: Product Profile - Orteronel 108
Table 47: Orteronel SWOT Analysis, 2012 112
Table 48: Product Profile - Alpharadin (radium-223 chloride) 113
Table 49: Alpharadin SWOT Analysis, 2012 117
Table 50: Product Profile - Tasquinimod 118
Table 51: Tasquinimod SWOT Analysis, 2012 121
Table 52: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 122
Table 53: ProstVac SWOT Analysis, 2012 126
Table 54: Sales Forecasts ($m) for Prostate Cancer in Japan, 2012-2022 128
Table 55: Key Events Impacting Sales for Prostate Cancer in Japan, 2012-2022 130
Table 56: Prostate Cancer Market in Japan - Drivers and Barriers, 2012 130
Table 57: Key Launch Dates 150
Table 58: Key Patent Expiries and Market Exclusivity Expiries 151
Table 59: Physicians Surveyed, By Country 165
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 19
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 89
Figure 3: Sales for Prostate Cancer in the Japan by Drug Class, 2012-2022 129